Dr Dónal Landers

Dónal Landers, Digital ECMT

Donal Landers headshot

Dónal Landers is Strategic Director of the digital Experimental Cancer Medicine Team. The digital ECMT is a clinical decision science research group part of Cancer Research UK Manchester Institute. Its mission is to provide next generation patient cancer care through comprehensive data-driven evidence to enable the transformation of clinical decision-making, the evolution the role of the patient and the improvement of patient outcomes.

 

After obtaining his primary medical degree from Trinity College, Dublin, Dónal spent several years in practicing in medicine as a clinical research registrar in HIV medicine and Infectious Diseases. He undertook an MBA at University College Dublin before transitioning to hospital senior management at St. James’s academic teaching hospital, in Dublin, where he led the clinical informatics group, a role which encompassed casemix development, clinical performance improvement, clinical and health informatics and computer science research (Dublin City University). Dónal later co-founded his own health informatics company developing patient ‘centric’ mobile technology solutions, which enabled patients to collect and monitor their own health data (diabetes). After a number of years in various technology start-up companies, he joined PricewaterhouseCoopers as a specialist senior consultant and became sectoral lead for the healthcare and pharmaceutical industry. Dónal joined AstraZeneca (AZ) in 2010 as pharmaceutical physician role in Early Clinical Development (ECD). He has recently worked as Senior Director Physician ECD and led AZ’s first large multi-drug oncology ‘umbrella’ study in urothelial cancer (BISCAY). Since leaving AZ, he has set up his own specialist consulting business, DeLondra Oncology, specializing in early clinical and translational drug development in oncology.

Dónal is a specialist in Pharmaceutical Medicine and a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians and has fully completed his specialist training (CCT). He also holds a Postgraduate Certificate in Translational Medicine from the University of Manchester and is fully registered on the GMC specialist register. He is a full member of ASCO and ESMO.